An experimental stem cell therapy in Geron's pipeline produced some promising preclinical results for glioblastoma brain cancer and prostate cancer. Researchers say that imetelstat (also called GRN163L), was able to cross the blood/brain barrier and inhibited 60 percent to 70 percent of the tumors implanted in mice. The therapy is in multiple Phase I studies and is scheduled to begin Phase II trials later this year. Report